Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd

$CAPLIPOINTPharmaceuticalsNSEBSE

Caplin Point Laboratories Ltd (CAPLIPOINT) last traded at ₹2,471, a market capitalisation of ₹18,780 crore, on a P/E of 28.3. Over the past 52 weeks the stock has ranged between ₹1,500 and ₹2,700. Caplin Point Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹610 crore and net profit of ₹179 crore. The next scheduled event is a record date on 18 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Caplin Point Laboratories Ltd share price and key metrics

Current price
₹2,471
Market cap
₹18,780 cr
Stock P/E
28.3
Book value
₹472
ROE
20.6%
ROCE
24.6%
Dividend yield
0.32%
52w high / low
2700/1500

Metrics as of 25 Aug 2026. Not real time.

Caplin Point Laboratories Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹610 cr, up 19.6% from ₹510 cr a year earlier. Net profit was ₹179 cr, up 18.5% year on year.

Caplin Point Laboratories Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales483493502510534543600610
Expenses318331334332345353396397
Operating profit165162168178189190204213
OPM %34%33%33%35%35%35%34%35%
Other income2131262330342834
Interest00000000
Depreciation1716171618191922
Profit before tax168177177184201204213225
Tax %22%21%18%18%20%19%19%20%
Net profit131140145151160166173179
EPS (₹)17.2118.2818.7620.1020.3221.5622.3823.27

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Caplin Point Laboratories Ltd annual results

Caplin Point Laboratories Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,0611,2691,4671,6941,9372,1872,287
Operating profit329395442552651761797
OPM %31%31%30%33%34%35%35%
Net profit251308377461541650678
EPS (₹)32.0339.5649.5760.1970.5684.3687.53

TTM is the trailing twelve months to the most recent quarter.

Caplin Point Laboratories Ltd growth and returns

Compounded Sales Growth
10 Years
25%
5 Years
16%
3 Years
14%
TTM
15%
Compounded Profit Growth
10 Years
30%
5 Years
22%
3 Years
20%
TTM
18%
Stock Price CAGR
10 Years
26%
5 Years
28%
3 Years
35%
1 Year
15%
Return on Equity
10 Years
25%
5 Years
23%
3 Years
22%
Last Year
21%

Caplin Point Laboratories Ltd shareholding pattern

Promoters held 70.57% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.76% and DIIs 2.49%.

Caplin Point Laboratories Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters70.56%70.56%70.56%70.56%70.57%70.57%70.57%70.57%
FIIs3.71%4.86%5.73%6.16%6.51%6.58%6.15%5.76%
DIIs1.83%2.11%2.00%2.22%2.10%2.05%2.14%2.49%
Public23.93%22.48%21.72%21.06%20.82%20.81%21.14%21.19%
No. of shareholders96,12392,70296,38794,16993,75393,70593,89694,385

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Upcoming Caplin Point Laboratories Ltd events

The next scheduled event is a record date on 18 Sept 2026.

  • Record dateRecord date for 35th AGM and payment of final dividend
  • AGM35th Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

Caplin Point Laboratories Ltd corporate filings

  • Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories announced that its subsidiary, Caplin Steriles Limited, has…

    Read the full analysis
  • Transcript for Earnings call- Q1- FY 2026-27Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories Limited has formally filed the transcript of its Q1 FY 2026-27…

    Read the full analysis
  • Audio Recording of Earnings call for the Quarter ended June 30, 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories Limited has formally filed the audio recording of its Q1 FY…

    Read the full analysis
  • The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories Limited has announced the re-appointment of Dr. Sridhar Ganesan…

    Read the full analysis
  • Record date for Final Dividend is September 18, 2026Corp. Actionlow impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories Limited has scheduled its 35th Annual General Meeting for…

    Read the full analysis
  • Board meeting outcome for meeting held on August 12, 2026Board Meetinghigh impact
    Filing PDF

    Cruxal's analysis: Caplin Point Laboratories Limited delivered a robust performance for the quarter ended…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Caplin Point Laboratories Ltd

Cruxal reads every Caplin Point Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Caplin Point Laboratories Ltd (CAPLIPOINT) Results, Financials & Share Price | Cruxal